表紙
市場調查報告書

抗病毒藥物市場分析:各作用機制(核苷酸聚合酵素抑制劑,逆轉錄酵素抑制劑,蛋白分解酵素抑制劑),各用途(HIV,肝炎,HSV,流感),各類型(學名藥,品牌藥),市場區隔預測

Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application (HIV, Hepatitis, Influenza), By Type (Branded, Generic), By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 478636
出版日期 內容資訊 英文 80 Pages
商品交期: 2-3個工作天內
價格
抗病毒藥物市場分析:各作用機制(核苷酸聚合酵素抑制劑,逆轉錄酵素抑制劑,蛋白分解酵素抑制劑),各用途(HIV,肝炎,HSV,流感),各類型(學名藥,品牌藥),市場區隔預測 Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application (HIV, Hepatitis, Influenza), By Type (Branded, Generic), By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月07日內容資訊: 英文 80 Pages
簡介

本報告提供全球抗病毒藥物市場相關調查,彙整市場趨勢,各作用機制,各用途,各類型,各地區趨勢,打入市場的主要企業簡介等資料。

第1章 調查方法及範圍

第2章 摘要整理

第3章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
    • 嚴厲的法律規章方案
  • 滲透與成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第4章 各作用機制預測與趨勢分析

  • 各作用機制趨勢分析及市場佔有率
  • 核苷酸聚合酵素抑制劑
  • 逆轉錄酵素抑制劑
  • 蛋白分解酵素抑制劑
  • 其他

第5章 各類型預測與趨勢分析

  • 各類型趨勢分析
  • 學名藥
  • 品牌藥

第6章 各用途預測與趨勢分析

  • 各用途趨勢分析
  • HIV
  • 肝炎
  • 皰疹病毒
  • 流感
  • 其他

第7章 各地區預測與趨勢分析

  • 市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入類別
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-389-8

The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of -2.3% over the forecast period. Increasing geriatric population is considered to be the major factor anticipated to drive the demand for efficient treatment of human immunodeficiency virus (HIV) infections.

According to the Centers of Disease Control and Prevention (CDC), nearly half the people diagnosed with HIV in U.S. are aged 50 and older. Furthermore, according to the data published in World Population Prospects: The 2019 Revision, one in six people globally is estimated to be over age of 65 years by 2050. In addition, one in four persons living in Northern America and Europe would be aged 65 years and above by 2050. The number of persons aged 80 years and above is estimated to triple, from 143 million in 2019 to 426 million in 2050. The increasing aging population worldwide would have a direct impact on the healthcare systems, who would have to meet the needs of the aging population. This, in turn, would drive the demand for antiviral drugs, which can be used to treat a range of viral infections.

Presence of pipeline antiviral products for HIV therapeutics is anticipated to drive the market over the forecast period. For instance, ViiV Healthcare is developing Cabotegravir/rilpivirine (long-acting injectable), which is currently under Phase III and are types of NNRTI/ INSTI drug class. In addition,GS-6207 (capsid inhibitor) and vesatolimod (TLR-7 agonist) are being developed by Gilead Sciences and are currently under Phase I trial for the treatment of HIV. Moreover, advancements in epidemiology and growing awareness of viral diseases are expected to result in a high demand for efficient treatment solutions.

According to the CDC, the prevalence of oral herpes (HSV-1) and genital herpes (HSV-2) was 47.8% and 11.9% respectively, from 2015 to 2016. The Herpes Resource Center (HRC) provides public awareness, education, and patient support. Moreover, the Hepatitis B Foundation provides information such as diagnosis, preventive measures, and treatment. Increasing preventive measures with the availability of various vaccines is expected to hinder the market growth over the forecast period.

Further key findings from the report suggest:

  • Reverse transcriptase inhibitors held the largest share in 2019 and is estimated to be the fastest-growing segment over the forecast period as these inhibitors slow down or prevent viral replication
  • DNA polymerase inhibitors was the second-largest segment in 2019 owing to its effectiveness in combating drug resistance
  • Generic products are estimated to be the fastest-growing segment over the forecast period owing to increased adoption of generic drugs in developing countries
  • Hepatitis dominated the application segment in 2019 owing to the availability of various antiviral products for its treatment
  • HIV is estimated to be the fastest-growing segment over the forecast period due to its increasing prevalence and incidence rate

North America dominated the global antiviral drugs market in 2019 owing to the presence of key players in the region and the availability of a well-established healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third-party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antiviral Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent/ Ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Pipeline Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increasing prevalence of viral infections such as hepatitis and HIV
      • 3.4.1.2. Presence of pipeline products for HIV treatment
      • 3.4.1.3. Increasing geriatric population
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Presence of generics
      • 3.4.2.2. Rising awareness and preventive treatments
  • 3.5. Antiviral Drugs: Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier Power
      • 3.5.1.2. Buyer Power
      • 3.5.1.3. Substitution Threat
      • 3.5.1.4. Threat from new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political Landscape
      • 3.5.2.2. Environmental Landscape
      • 3.5.2.3. Social Landscape
      • 3.5.2.4. Technology Landscape
      • 3.5.2.5. Legal Landscape

Chapter 4. Antiviral Drugs Market: Segment Analysis, By Drug Class, 2016 - 2027 (USD Billion)

  • 4.1. Definitions & Scope
  • 4.2. Drug class market share analysis, 2019 & 2027
  • 4.3. Segment Dashboard
  • 4.4. Global Antiviral Drugs Market, By Drugs Class, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 4.5.1. DNA Polymerase Inhibitors
    • 4.5.2. Reverse Transcriptase Inhibitors
    • 4.5.3. Protease Inhibitors
    • 4.5.4. Neuraminidase Inhibitors
    • 4.5.5. Others

Chapter 5. Antiviral Drugs Market: Segment Analysis, By Type, 2016 - 2027 (USD Billion)

  • 5.1. Definitions & Scope
  • 5.2. Type market share analysis, 2019 & 2027
  • 5.3. Segment Dashboard
  • 5.4. Global Antiviral Drugs Market, By Type, 2016 to 2027
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.5.1. Branded
    • 5.5.2. Generics

Chapter 6. Antiviral Drugs Market: Segment Analysis, By Application, 2016 - 2027 (USD Billion)

  • 6.1. Definitions & Scope
  • 6.2. Application market share analysis, 2019 & 2027
  • 6.3. Segment Dashboard
  • 6.4. Global Antiviral Drugs Market, By Application, 2016 to 2027
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 6.5.1. HIV
    • 6.5.2. Hepatitis
    • 6.5.3. Herpes
    • 6.5.4. Influenza
    • 6.5.5. Others

Chapter 7. Antiviral Drugs Market: Regional Market Analysis, By Region, 2016 - 2027 (USD Billion)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2019 & 2027
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Share and Leading Players, 2019
  • 7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. Market Size, & Forecasts and Trend Analysis, 2019 to 2027
  • 7.7. North America
    • 7.7.1 Market estimates and forecast, by country, 2016 - 2027 (USD Billion)
    • 7.7.2 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
    • 7.7.3 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
    • 7.7.4 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.7.5 U.S.
      • 7.7.5.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.7.5.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.7.5.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.7.6 Canada
      • 7.7.6.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.7.6.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.7.6.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
  • 7.8. Europe
    • 7.8.1 Market estimates and forecast, by country, 2016 - 2027 (USD Billion)
    • 7.8.2 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
    • 7.8.3 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
    • 7.8.4 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.8.5 Germany
      • 7.8.5.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.8.5.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.8.5.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.8.6 U.K.
      • 7.8.6.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.8.6.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.8.6.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.8.7 France
      • 7.8.7.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.8.7.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.8.7.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.8.8 Italy
      • 7.8.8.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.8.8.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.8.8.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.8.9 Spain
      • 7.8.9.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.8.9.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.8.9.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
  • 7.9 Asia Pacific
    • 7.9.1 Market estimates and forecast, by country, 2016 - 2027 (USD Billion)
    • 7.9.2 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
    • 7.9.3 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
    • 7.9.4 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.9.5 China
      • 7.9.5.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.9.5.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.9.5.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.9.6 Japan
      • 7.9.6.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.9.6.2 Market estimates and forecast, by type2016 - 2027 (USD Billion)
      • 7.9.6.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.9.7 India
      • 7.9.7.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.9.7.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.9.7.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.9.8 Australia
      • 7.9.8.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.9.8.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.9.8.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.9.9 South Korea
      • 7.9.9.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.9.9.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.9.9.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
  • 7.10 Latin America
    • 7.10.1 Market estimates and forecast, by country, 2016 - 2027 (USD Billion)
    • 7.10.2 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
    • 7.10.3 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
    • 7.10.4 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.10.5 Brazil
      • 7.10.5.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.10.5.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.10.5.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.10.6 Mexico
      • 7.10.6.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.10.6.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.10.6.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.10.7 Argentina
      • 7.10.7.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.10.7.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.10.7.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.10.8 Colombia
      • 7.10.8.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.10.8.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.10.8.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
  • 7.11 Middle East and Africa
    • 7.11.1 Market estimates and forecast, by country, 2016 - 2027 (USD Billion)
    • 7.11.2 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
    • 7.11.3 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
    • 7.11.4 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.11.5 South Africa
      • 7.11.5.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.11.5.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.11.5.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.11.6 Saudi Arabia
      • 7.11.6.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.11.6.2 Market estimates and forecast, by type2016 - 2027 (USD Billion)
      • 7.11.6.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)
    • 7.11.7 UAE
      • 7.11.7.1 Market estimates and forecast, by drug class, 2016 - 2027 (USD Billion)
      • 7.11.7.2 Market estimates and forecast, by type, 2016 - 2027 (USD Billion)
      • 7.11.7.3 Market estimates and forecast, by application, 2016 - 2027 (USD Billion)

Chapter 8. Antiviral drugs market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Public Companies
    • 8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.3.2. Company Market Share/Ranking, by region
    • 8.3.3. Competitive Dashboard Analysis
  • 8.4. Private Companies
    • 8.4.1. List of key emerging companies/technology disruptors/innovators
    • 8.4.2. Regional network map
    • 8.4.3. Company market position analysis
  • 8.5. Key companies profiled
    • 8.5.1. Gilead Sciences
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F. Hoffmann-La Roche AG
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. GlaxoSmithKline plc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. AbbVie
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Johnson & Johnson Services, Inc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bristol-Myers Squibb Company
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Cipla Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Aurobindo Pharma
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Dr. Reddy's Laboratories Ltd.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Abbreviations
  • TABLE 2 North America Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 3 North America Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 4 North America Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 5 U.S. Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 6 U.S. Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 7 U.S. Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 8 Canada Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 9 Canada Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 10 Canada Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 11 Europe Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 12 Europe Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 13 Europe Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 14 Germany Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 15 Germany Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 16 Germany Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 17 U.K. Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 18 U.K. Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 19 U.K. Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 20 Italy Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 21 Italy Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 22 Italy Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 23 France Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 24 France Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 25 France Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 26 Spain Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 27 Spain Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 28 Spain Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 29 Asia Pacific Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 30 Asia Pacific Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 31 Asia Pacific Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 32 Japan Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 33 Japan Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 34 Japan Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 35 China Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 36 China Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 37 China Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 38 India Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 39 India Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 40 India Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 41 South Korea Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 42 South Korea Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 43 South Korea Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 44 Australia Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 45 Australia Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 46 Australia Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 47 Latin America Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 48 Latin America Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 49 Latin America Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 50 Brazil Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 51 Brazil Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 52 Brazil Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 53 Mexico Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 54 Mexico Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 55 Mexico Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 56 Argentina Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 57 Argentina Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 58 Argentina Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 59 Colombia Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 60 Colombia Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 61 Colombia Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 62 MEA Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 63 MEA Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 64 MEA Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 65 South Africa Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 66 South Africa Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 67 South Africa Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 68 UAE Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 69 UAE Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 70 UAE Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)
  • TABLE 71 Saudi Arabia Antiviral Drugs Market, By Drug Class, 2016 - 2027 (USD Billion)
  • TABLE 72 Saudi Arabia Antiviral Drugs Market, By Type, 2016 - 2027 (USD Billion)
  • TABLE 73 Saudi Arabia Antiviral Drugs Market, By Application, 2016 - 2027 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global antiviral drugs market - Key market driver analysis
  • FIG. 7 Global antiviral drugs market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global antiviral drugs market - Porter's analysis
  • FIG. 10 Global antiviral drugs market - PESTEL analysis
  • FIG. 11 Global antiviral drugs market drug class outlook key takeaways
  • FIG. 12 Global antiviral drugs market: Drug class movement analysis
  • FIG. 13 DNA polymerase inhibitors market estimates, 2016 - 2027 (USD Billion)
  • FIG. 14 Reverse transcriptase inhibitors market estimates, 2016 - 2027 (USD Billion)
  • FIG. 15 Protease inhibitors market estimates, 2016 - 2027 (USD Billion)
  • FIG. 16 Neuraminidase inhibitors market estimates, 2016 - 2027 (USD Billion)
  • FIG. 17 Others market estimates, 2016 - 2027 (USD Billion)
  • FIG. 18 Global antiviral drugs market Type outlook key takeaways
  • FIG. 19 Global antiviral drugs market: Type movement analysis
  • FIG. 20 Branded market estimates, 2016 - 2027 (USD Billion)
  • FIG. 21 Generics market estimates, 2016 - 2027 (USD Billion)
  • FIG. 22 Global antiviral drugs market Application outlook key takeaways
  • FIG. 23 Global antiviral drugs market: Application movement analysis
  • FIG. 24 HIV market estimates, 2016 - 2027 (USD Billion)
  • FIG. 25 Hepatitis market estimates, 2016 - 2027 (USD Billion)
  • FIG. 26 Herpes market estimates, 2016 - 2027 (USD Billion)
  • FIG. 27 Influenza market estimates, 2016 - 2027 (USD Billion)
  • FIG. 28 Others market estimates, 2016 - 2027 (USD Billion)
  • FIG. 29 Regional marketplace: Key takeaways
  • FIG. 30 Global antiviral drugs market: Regional movement analysis
  • FIG. 31 North America antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 32 U.S. antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 33 Canada antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 34 Europe antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 35 U.K. antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 36 Germany antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 37 France antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 38 Spain antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 39 Italy antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 40 Asia Pacific antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 41 Japan antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 42 China antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 43 India antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 44 South Korea antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 45 Australia antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 46 Latin America antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG 47 Brazil antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 48 Mexico antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 49 Argentina antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 50 Colombia antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 51 MEA antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 52 South Africa antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 53 Saudi Arabia antiviral drugs market, 2016 - 2027 (USD Billion)
  • FIG. 54 UAE market, 2016 - 2027 (USD Billion)
  • FIG. 55 Strategy framework